

## AMENDMENT

### In the Claims:

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1. (Currently amended) A method for ~~antigen-independent activation~~ of activating T cells, *in vivo*, comprising contacting T cells independent of antigen with a combination of ~~at least two cytokines selected from the group consisting of~~ interleukin-2, interleukin-6, and tumor necrosis factor alpha, or functionally equivalent fragments thereof.

2. (Cancelled)

3. (Previously presented) The method of claim 1, wherein the T cells are naive T cells and/or memory resting T cells.

4. (Previously presented) The method of claim 1, wherein the T cells are naive CD45RA+ cells and/or memory resting CD45RO+ cells.

5. (Currently amended) The method of claim 1, wherein the concentration of interleukin-2 contacted with the cells is from 100 to 400 U/ml, the concentration of interleukin-6 contacted with the cells is from 400 to 600 U/ml and the concentration of tumour necrosis factor  $\alpha$  contacted with the cells is from 15 to 35 ng/ml.

6. (Currently amended) The method of claim 1, wherein the

concentration of interleukin-2 contacted with the cells is from 200 to 300 U/ml, the concentration of interleukin-6 contacted with the cells is about 500 U/ml and the concentration of tumour necrosis factor  $\alpha$  contacted with the cells is about 25 ng/ml.

7-9. (Cancelled)

10. (Previously presented) The method of any of the preceding claims, wherein the activation of the T cells *in vivo* leads to an enhanced immunological response.

11. (Previously presented) A method of therapy comprising activating in a human or animal subject T cells using the method of claim 10.

12. (Cancelled)